Sigma-Aldrich Grants Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
News Jan 04, 2007
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology.
Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia. This research license will provide Pfizer with freedom to use ddRNAi in undertaking research activities throughout its global operations. Financial details were not disclosed.
Shaf Yousaf, President of the Sigma-Aldrich Research Biotechnology business unit, said, "ddRNAi has important research applications and future potential for therapeutic development.”
“Following our research collaboration with The RNAi Consortium licenses to key RNAi intellectual property, Sigma- Aldrich has an intellectual property portfolio in RNAi that positions us well for a comprehensive out-licensing program as well as market leadership in RNAi research reagents," he said.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019